Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC 50 of 91 nM. In Vivo Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice . Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J mice . Dosage: 100 mg/kg. Administration: I.G. (gavage) once daily for 7 days. Result: Significantly decreased the plasma SM levels compared with vehicle group. Animal Model: ApoE KO mice (eight-week-old) . Dosage: 12.5 or 40 mg/kg. Administration: I.G. (gavage) once daily. Result: The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Ly93
CAS number：1883528-69-5 molecular formula：C21H20N2O2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1883528-69-5 | molecular formula | C21H20N2O2 |
| molecular weight | 332.40 g/mol | Exact mass | ≥99% |
| PSA | 51.200 Ų | logp | 3.900 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
